CO2024002573A2 - Síntesis de nirogacestat - Google Patents

Síntesis de nirogacestat

Info

Publication number
CO2024002573A2
CO2024002573A2 CONC2024/0002573A CO2024002573A CO2024002573A2 CO 2024002573 A2 CO2024002573 A2 CO 2024002573A2 CO 2024002573 A CO2024002573 A CO 2024002573A CO 2024002573 A2 CO2024002573 A2 CO 2024002573A2
Authority
CO
Colombia
Prior art keywords
nirogacestat
synthesis
neopentylamino
pentanamide
tetrahydronaphthalen
Prior art date
Application number
CONC2024/0002573A
Other languages
English (en)
Inventor
Kristin Patterson
Mark Hatcher
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of CO2024002573A2 publication Critical patent/CO2024002573A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/26—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing carboxyl groups by reaction with HCN, or a salt thereof, and amines, or from aminonitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)

Abstract

La presente descripción se dirige a procesos para la síntesis de (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahidronaftalen-2-il)amino)-N-(1-(2-metil-1-(neopentilamino)propan-2-il)-1H-imidazol-4-il)pentanamida ("nirogacestat").
CONC2024/0002573A 2021-09-01 2024-02-29 Síntesis de nirogacestat CO2024002573A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163239696P 2021-09-01 2021-09-01
PCT/US2022/075839 WO2023034917A1 (en) 2021-09-01 2022-09-01 Synthesis of nirogacestat

Publications (1)

Publication Number Publication Date
CO2024002573A2 true CO2024002573A2 (es) 2024-03-07

Family

ID=85413129

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0002573A CO2024002573A2 (es) 2021-09-01 2024-02-29 Síntesis de nirogacestat

Country Status (10)

Country Link
US (3) US20230089434A1 (es)
KR (1) KR20240056726A (es)
CN (1) CN118043305A (es)
AR (1) AR126961A1 (es)
AU (1) AU2022339841A1 (es)
CA (1) CA3230245A1 (es)
CO (1) CO2024002573A2 (es)
IL (1) IL311128A (es)
TW (1) TW202328068A (es)
WO (1) WO2023034917A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533554A1 (en) * 2003-08-01 2005-02-10 Pfizer Products Inc. 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders
PL1730119T3 (pl) * 2004-03-23 2008-10-31 Pfizer Products Incorporated Związki imidazolowe do leczenia zaburzeń neurodegeneracyjnych
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
WO2007034326A2 (en) * 2005-09-22 2007-03-29 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
US10590087B1 (en) * 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
US20230312480A1 (en) 2023-10-05
CA3230245A1 (en) 2023-03-09
WO2023034917A1 (en) 2023-03-09
AU2022339841A1 (en) 2024-03-28
TW202328068A (zh) 2023-07-16
AR126961A1 (es) 2023-12-06
US20230089434A1 (en) 2023-03-23
CN118043305A (zh) 2024-05-14
IL311128A (en) 2024-04-01
KR20240056726A (ko) 2024-04-30
US20230091415A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
MX2019008378A (es) Proceso para la sintesis de un inhibidor de indolamina 2,3-dioxigenasa.
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
RS53627B1 (en) N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
DE60335827D1 (de) 1-(amino)indane als edg-rezeptoragonisten
CY1113547T1 (el) Διαδικασια συνθεσης ενωσεων χρησιμων στην αντιμετωπιση της ηπατιτιδας c
MA29619B1 (fr) Derive de 1,1 -dioxyde de 1,4-benzothiazepine, procede de preparation, medicaments comprenant ce compose, et utilisation de celui-ci comme hypolipidemiant
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
UY30617A1 (es) Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones
DE60329073D1 (de) Edg-rezeptoragonisten
PT1251848E (pt) Inibidores de girase e as sua utilizacoes
PH12019502154A1 (en) 6-pyrimidin-isoindole derivative as erk1/2 inhibitor
GEP20166443B (en) Heterocyclic compound and use thereof
CO2022002731A2 (es) Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE60120881D1 (de) Sulfonamide als matrix-metalloproteinase inhibitoren
EA202091082A1 (ru) Композиция и способ лечения периферической т-клеточной лимфомы и кожной т-клеточной лимфомы
CO2024002573A2 (es) Síntesis de nirogacestat
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci
ATE398612T1 (de) Diastereoselektive addition von lithiiertem n- methylimidazol an sulfinimine
ZA202207850B (en) Methods, processes and intermediates for preparing chroman compounds
AU2021300281A8 (en) RORγt inhibitors and topical uses thereof
MX2022003830A (es) Compuesto de n-(1h-imidazol-2-il)benzamida y composicion farmaceutica que comprende el mismo como ingrediente activo.
MX2022002187A (es) Composicion de amida peptidica y metodo para su preparacion.